US2014155369A1PendingUtilityA1

Preventives/remedies for stress urinary incontinence and method of screening the same

47
Assignee: TAKEDA PHARMACEUTICALPriority: Aug 25, 2004Filed: Jan 16, 2014Published: Jun 5, 2014
Est. expiryAug 25, 2024(expired)· nominal 20-yr term from priority
Inventors:Izumi KamoTadatoshi Hashimoto
A61P 43/00A61P 5/26A61P 25/02A61P 3/10A61K 31/55A61P 13/10A61K 31/542A61K 31/4045A61K 31/165A61P 13/02A61K 31/4025A61K 31/435A61K 31/381A61K 31/416A61K 31/551A61K 31/495A61K 31/5383A61K 31/137A61P 13/00A61P 15/00A61K 31/136A61K 31/497A61K 31/568A61K 31/496G01N 33/5088A61K 31/4985A61K 31/5375A61K 31/5517A61K 31/437A61K 31/397A61K 31/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT 2C receptor, an agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that stimulates an androgen binding site, and a method of screening for a drug for the prophylaxis or treatment of abdominal pressure incontinence, which includes electrostimulating the abdominal muscles or a nerve controlling them of an animal to increase the abdominal pressure, and measuring the leak point pressure at that time.

Claims

exact text as granted — not AI-modified
1 . An agent for the prophylaxis or treatment of stress urinary incontinence, which comprises a substance that activates a serotonin 5-HT 2C  receptor. 
     
     
         2 . The agent of  claim 1 , wherein the substance that activates a serotonin 5-HT 2C  receptor is a serotonin 5-HT 2C  receptor agonist. 
     
     
         3 - 14 . (canceled)

Join the waitlist — get patent alerts

Track US2014155369A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.